{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:46:11Z","timestamp":1793666771377,"version":"4.5.1"},"reference-count":195,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR)-T-cell therapy has garnered significant attention for its transformative impact on the treatment of hematologic malignancies such as leukemia and lymphoma. Despite its remarkable success, challenges such as resistance, limited efficacy in solid tumors, and adverse side effects remain prominent. This review consolidates recent advancements in CAR-T-cell therapy and explores innovative engineering techniques and strategies to overcome the immunosuppressive tumor microenvironment (TME). We also discuss emerging applications beyond cancer, including autoimmune diseases and chronic infections. Future perspectives highlight the development of more potent CAR-T cells with increased specificity and persistence and reduced toxicity, providing a roadmap for next-generation immunotherapies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1544532","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T01:52:41Z","timestamp":1739929961000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond"],"prefix":"10.3389","volume":"16","author":[{"given":"Zishan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjun","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhinan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40425-017-0230-9","article-title":"Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment","volume":"5","author":"Irene","year":"2017","journal-title":"J ImmunoTherapy Cancer."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2009489","DOI":"10.1002\/adfm.202009489","article-title":"Delivery techniques for enhancing CAR T cell therapy against solid tumors","volume":"31","author":"Fu","year":"2021","journal-title":"Advanced Funct Materials."},{"key":"B4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-020-00890-6","article-title":"Gene modification strategies for next-generation CAR T cells against solid cancers","volume":"13","author":"Tian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"[amp]]lsquo;Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discovery."},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687822","article-title":"Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1053120","article-title":"Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance","volume":"13","author":"Qin","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618387","article-title":"Befriending the hostile tumor microenvironment in CAR T-cell therapy","volume":"11","author":"Lindo","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1512411","article-title":"Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia","volume":"18","author":"Leahy","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.03.002","article-title":"CARs: synthetic immunoreceptors for cancer therapy and beyond","volume":"23","author":"Chang","year":"2017","journal-title":"Trends Mol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02711","article-title":"CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases","volume":"10","author":"Seif","year":"2019","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"188930","DOI":"10.1016\/j.bbcan.2023.188930","article-title":"Time to abandon CAR-T monotherapy for solid tumors","volume":"1878","author":"Yin","year":"2023","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1045024","article-title":"Bright future or blind alley CAR-T cell therapy for solid tumors","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine."},{"key":"B29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity."},{"key":"B31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discovery."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc Of Natl Acad Of Sci Of United States Of America."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature05071","article-title":"Centrosome polarization delivers secretory granules to the immunological synapse","volume":"444","author":"Stinchcombe","year":"2006","journal-title":"Nature."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.9.5.1031","article-title":"Targeting the Fas\/Fas ligand pathway in cancer","volume":"9","author":"O\u2019Brien","year":"2005","journal-title":"Expert Opin On Ther Targets."},{"key":"B37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s40425-018-0385-z","article-title":"CART cells are prone to Fas- and WDR5-mediated cell death","volume":"6","author":"Tschumi","year":"2018","journal-title":"J For Immunotherapy Of Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"pg 885","DOI":"10.1038\/cdd.2015.3","article-title":"The role of CD95 and CD95 ligand in cancer","volume":"22","author":"Peter","year":"2015","journal-title":"Cell Death And Differentiation."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.153","article-title":"Programmed cell death and the immune system","volume":"17","author":"Nagata","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0065","article-title":"CD30-redirected chimeric antigen receptor T cells target CD30+ and CD30\u2013 embryonal carcinoma via antigen-dependent and fas\/fasL interactions","volume":"6","author":"Hong","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 Receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00570-7","article-title":"Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-\u03b3 is a major determinant of CD4+ CAR T-cell antitumor activity","volume":"4","author":"Boulch","year":"2023","journal-title":"Nat Cancer."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00383-0","article-title":"Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors","volume":"3","author":"Zhang","year":"2022","journal-title":"Nat Cancer."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.10.026","article-title":"CAR T therapy extends its reach to autoimmune diseases","volume":"185","author":"Baker","year":"2022","journal-title":"Cell."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Trans Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06076-2","article-title":"Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes","volume":"67","author":"Tuomela","year":"2024","journal-title":"Diabetologia."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.23","article-title":"T-cell therapies for HIV","volume":"5","author":"Lam","year":"2013","journal-title":"Immunotherapy."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0121","article-title":"Chimeric antigen receptor engineered stem cells: a novel HIV therapy","volume":"9","author":"Zhen","year":"2017","journal-title":"Immunotherapy."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00361","article-title":"Advances in developing CAR T-cell therapy for HIV cure","volume":"11","author":"Qi","year":"2020","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-021-00121-8","article-title":"Strategies for targeting senescent cells in human disease","volume":"1","author":"Gasek","year":"2021","journal-title":"Nat Aging."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.23.529737","article-title":"Insulin B peptide-MHC class II-specific chimeric antigen receptor-Tregs prevent autoimmune diabetes","volume":"23","author":"Spanier","year":"2023","journal-title":"bioRxiv."},{"key":"B55","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmunity."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Trans Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","article-title":"Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation","volume":"36","author":"Shan","year":"2012","journal-title":"Immunity."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nature14053","article-title":"Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations","volume":"517","author":"Deng","year":"2015","journal-title":"Nature."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectabl plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature."},{"key":"B61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v12.10","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","volume":"11","author":"Jia","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discovery."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discovery."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1182\/blood-2018-99-115351","article-title":"Aged CAR T cells exhibit enhanced cytotoxicity and effector function but shorter persistence and less memory-like phenotypes","volume":"132","author":"Kotani","year":"2018","journal-title":"Blood."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the mechanisms of resistance to CAR T-cell therapy in Malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discovery"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nri2095","article-title":"TGFbeta signalling in control of T-cell-mediated self-reactivity","volume":"7","author":"Rubtsov","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000559","article-title":"Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies","volume":"27","author":"Sterner","year":"2020","journal-title":"Curr Opin Hematology."},{"key":"B78","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jha2.v3.S1","article-title":"CAR T cell therapy in solid tumors: A review of current clinical trials","volume":"3","author":"Patel","year":"2022","journal-title":"eJHaem."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor\u2013modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","article-title":"Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment","volume":"12","author":"Yan","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19361","article-title":"Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities","volume":"8","author":"Xia","year":"2017","journal-title":"Oncotarget;"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: A therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00045","article-title":"High endothelial venules and other blood vessels: critical regulators of lymphoid organ development and function","volume":"8","author":"Ager","year":"2017","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2021.10.004","article-title":"Revisiting the HIF switch in the tumor and its immune microenvironment","volume":"8","author":"Cowman","year":"2022","journal-title":"Trends Cancer."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/med.21771","article-title":"The role of hypoxia-inducible factor 1 in tumor immune evasion","volume":"41","author":"You","year":"2021","journal-title":"Medicinal Res Rev"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.007","article-title":"Hypoxia, hypoxia-inducible transcription factors, and renal cancer","volume":"69","author":"Sch\u00f6del","year":"2016","journal-title":"Eur Urology."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/imr.2017.276.issue-1","article-title":"The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol Rev"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45559","article-title":"CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice","volume":"121","author":"Wang","year":"2011","journal-title":"J Clin Invest"},{"key":"B95","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"117534","DOI":"10.1016\/j.lfs.2020.117534","article-title":"CXCL12\/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis","volume":"249","author":"Mortezaee","year":"2020","journal-title":"Life Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01578","article-title":"Tregs: where we are and what comes next","volume":"8","author":"Zhao","year":"2017","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1038\/cti.2017.43","article-title":"Regulatory T-cell heterogeneity and the cancer immune response","volume":"6","author":"Ward-Hartstonge","year":"2017","journal-title":"Clin Transl Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.7150\/jca.30102","article-title":"High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3991","article-title":"Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity","volume":"25","author":"Tanegashima","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer","volume":"20","author":"Leone","year":"2020","journal-title":"Nat Rev Cancer."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.012","article-title":"Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses","volume":"162","author":"Ho","year":"2015","journal-title":"Cell."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127515","article-title":"Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy","volume":"130","author":"Sharma","year":"2020","journal-title":"J Clin Invest."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-020-01820-7","article-title":"Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy","volume":"40","author":"Wang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.molcel.2022.02.033","article-title":"Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells","volume":"82","author":"Xiong","year":"2022","journal-title":"Mol Cell"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00052","article-title":"Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance","volume":"7","author":"Romero-Garcia","year":"2016","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev Of Clin Immunol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B114","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Therapy-Oncolytics."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-730689","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"128","author":"Lee","year":"2016","journal-title":"Blood."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat Rev Drug DISCOVERY."},{"key":"B119","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunology Immunother"},{"key":"B121","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Trans Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Trans Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood."},{"key":"B124","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Trans Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Of Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Of Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv In Hematology."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl J Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B130","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"BLOOD."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discovery."},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B135","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell."},{"key":"B136","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12913-023-10443-5","article-title":"Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study","volume":"24","author":"Cavallo","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1182\/blood-2021-153438","article-title":"Total car-T cost of care beyond the price of car-T cell therapy in patients with multiple myeloma","volume":"138","author":"Jagannath","year":"2021","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-021-03067-z","article-title":"Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products","volume":"38","author":"Sadeqi Nezhad","year":"2021","journal-title":"Pharm Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.stem.2024.10.004","article-title":"Maturation and persistence of CAR T cells derived from human pluripotent stem cells via chemical inhibition of G9a\/GLP","volume":"32","author":"Jing","year":"2025","journal-title":"Cell Stem Cell"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2023.04.043","article-title":"Biomaterials for chimeric antigen receptor T cell engineering","volume":"166","author":"Niu","year":"2023","journal-title":"Acta Biomaterialia."},{"key":"B142","doi-asserted-by":"publisher","first-page":"101139","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","volume":"31","author":"Kitte","year":"2023","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1039\/D2NR05949E","article-title":"Potential roles of hyaluronic acid in in vivo CAR T cell reprogramming for cancer immunotherapy","volume":"14","author":"Laomeephol","year":"2022","journal-title":"Nanoscale."},{"key":"B144","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-bioeng-070620-033348","article-title":"In situ programming of CAR T cells","volume":"23","author":"Parayath","year":"2021","journal-title":"Annu Rev Biomed Engineering."},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat Nanotechnology."},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science."},{"key":"B147","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"B148","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: A new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther - Oncolytics."},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science."},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.01.005","article-title":"Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering","volume":"25","author":"Si","year":"2023","journal-title":"Cytotherapy."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.10.034","article-title":"Bioengineered nanotechnology for nucleic acid delivery","volume":"364","author":"Zhang","year":"2023","journal-title":"J Control Release."},{"key":"B155","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell."},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02078-y","article-title":"Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo","volume":"42","author":"An","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat5011","article-title":"CRISPR-Cas guides the future of genetic engineering","volume":"361","author":"Knott","year":"2018","journal-title":"Science."},{"key":"B158","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol Cancer."},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512317","article-title":"CRISPR\/cas9: A powerful strategy to improve CAR-T cell persistence","volume":"24","author":"Wei","year":"2023","journal-title":"Int J Mol Sci [Internet]."},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00456","article-title":"Building potent chimeric antigen receptor T cells with CRISPR genome editing","volume":"10","author":"Liu","year":"2019","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171626","article-title":"Optimized RNP transfection for highly efficient CRISPR\/Cas9-mediated gene knockout in primary T cells","volume":"215","author":"Seki","year":"2018","journal-title":"J Exp Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature."},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat Rev Genet"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13059-023-02928-7","article-title":"Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells","volume":"24","author":"Glaser","year":"2023","journal-title":"Genome Biol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat Rev Genet"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2023.03.004","article-title":"Prime editing: advances and therapeutic applications","volume":"41","author":"Zhao","year":"2023","journal-title":"Trends Biotechnol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41421-023-00552-0","article-title":"High-efficiency targeted transgene integration via primed micro-homologues","volume":"9","author":"Wang","year":"2023","journal-title":"Cell Discovery."},{"key":"B170","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal Kole","year":"2016","journal-title":"Cell."},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Trans Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci Transl Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6270","article-title":"Precise T cell recognition programs designed by transcriptionally linking multiple receptors","volume":"370","author":"Williams","year":"2020","journal-title":"Science."},{"key":"B177","doi-asserted-by":"publisher","first-page":"e20221988","DOI":"10.1084\/jem.20221988","article-title":"Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy","volume":"221","author":"Lin","year":"2024","journal-title":"J Exp Med"},{"key":"B178","doi-asserted-by":"publisher","first-page":"114354","DOI":"10.1016\/j.bcp.2020.114354","article-title":"Targeting tumor-associated macrophages as an antitumor strategy","volume":"183","author":"Cheng","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-1075","article-title":"Targeting macrophages with CAR T cells delays solid tumor progression and enhances antitumor immunity","volume":"10","author":"S\u00e1nchez-Paulete","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.7b00768","article-title":"CRISPRed macrophages for cell-based cancer immunotherapy","volume":"29","author":"Ray","year":"2018","journal-title":"Bioconjugate Chem"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"eLife."},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1186\/s12967-022-03813-w","article-title":"Targeting macrophages: a novel treatment strategy in solid tumors","volume":"20","author":"Liu","year":"2022","journal-title":"J Trans Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2593","article-title":"Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells","volume":"67","author":"Nefedova","year":"2007","journal-title":"Cancer Res"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1157537","article-title":"Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol Ther"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science."},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03161-1","article-title":"DC vaccine enhances CAR-T cell antitumor activity by overcoming T cell exhaustion and promoting T cell infiltration in solid tumors","volume":"25","author":"Zhang","year":"2023","journal-title":"Clin Trans Oncol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur J Immunol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-024-03648-y","article-title":"Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma","volume":"73","author":"Dai","year":"2024","journal-title":"Cancer Immunology Immunother"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1126\/science.add7034","article-title":"Probiotic-guided CAR-T cells for solid tumor targeting","volume":"382","author":"Vincent","year":"2023","journal-title":"Science."},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1218080110","article-title":"Modulating the innate immune response by combinatorial engineering of endotoxin","volume":"110","author":"Needham","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07018-7","article-title":"Naturally occurring T cell mutations enhance engineered T cell therapies","volume":"626","author":"Garcia","year":"2024","journal-title":"Nature."},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"B195","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1544532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T01:52:46Z","timestamp":1739929966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1544532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":195,"alternative-id":["10.3389\/fimmu.2025.1544532"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1544532","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"article-number":"1544532"}}